Complete Cytogenetic Response, Not Deep Molecular Response, Is Associated With Survival in Chronic Myeloid Leukemia Reply

被引：2
|
作者：
Hehlmann, Ruediger [1 ]
Hasford, Joerg [2 ]
Pfirrmann, Markus [2 ]
Lauseker, Michael [2 ]
Saussele, Susanne [1 ]
Hochhaus, Andreas [3 ]
机构：
[1] Heidelberg Univ, Univ Med Mannheim, Mannheim, Germany
[2] Univ Munich, Inst Med Informat Verarbeitung Biomet & Epidemiol, Munich, Germany
[3] Univ Klinkum Jena, Jena, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 27期
关键词：
KINASE INHIBITOR THERAPY; RECOMMENDATIONS; IMATINIB;
D O I：
10.1200/JCO.2014.56.3908
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3078 / +
页数：2
相关论文
共 50 条
  • [31] Early molecular response in chronic myeloid leukemia patients predicts future response status
    Kagita, Sailaja
    Jiwtani, Sangeeta
    Uppalapati, Srihari
    Linga, Vijay Gandhi
    Gundeti, Sadasivudu
    Digumarti, Raghunadharao
    TUMOR BIOLOGY, 2014, 35 (05) : 4443 - 4446
  • [32] The Clinical Significance of Achieving Different Levels of Cytogenetic Response in Patients With Chronic Phase Chronic Myeloid Leukemia After Failure to Front-Line Therapy: Is Complete Cytogenetic Response the Only Desirable Endpoint?
    Cortes, Jorge
    Quintas-Cardama, Alfonso
    Jabbour, Elias
    O'Brien, Susan
    Verstovsek, Srdan
    Borthakur, Gautam
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Burton, Elizabeth
    Shan, Jenny
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (05) : 421 - 426
  • [33] EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib
    Tao, Zhonfei
    Liu, Bingcheng
    Zhao, Yaozhong
    Wang, Ying
    Zhang, Rongli
    Han, Mingzhe
    Zhang, Li
    Li, Chengwen
    Ru, Kun
    Mi, Yingchang
    Wang, Jianxiang
    LEUKEMIA RESEARCH, 2014, 38 (09) : 1030 - 1035
  • [34] Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor
    Kyoko Inokura
    Yasushi Onishi
    Kenji Shimosegawa
    Yoko Okitsu
    Yuna Katsuoka
    Tohru Fujiwara
    Noriko Fukuhara
    Kenichi Ishizawa
    Hideo Harigae
    Annals of Hematology, 2012, 91 : 1825 - 1826
  • [35] Immunological status of chronic myelogenous leukemia patients with complete cytogenetic response after treatment
    Deng, Zhikui
    Li, Yuanyuan
    Li, Yu-feng
    TUMORI, 2015, 101 (03) : 323 - 327
  • [36] Lower than expected cytogenetic and molecular response to imatinib in Mexican patients with chronic myelogenous leukemia
    Homero Gutierrez-Aguirre, Cesar
    Garcia-Rodriguez, Fernando
    Manuel Ortiz-Galvez, Victor
    Graciela Cantu-Rodriguez, Olga
    Salazar-Riojas, Rosario
    Lizzette Martinez-Gonzalez, Odra
    Gonzalez-Llano, Oscar
    Carlos Jaime-Perez, Jose
    Ortiz-Lopez, Rocio
    Antonio Flores-Jimenez, Juan
    Alatorre-Ricardo, Julio
    Mancias-Guerra, Consuelo
    Gomez-Almaguer, David
    HEMATOLOGY, 2013, 18 (04) : 224 - 229
  • [37] Analyzing Molecular Response in Chronic Myeloid Leukemia Clinical Trials: Pitfalls and Golden Rules
    Guilhot, Joelle
    Preudhomme, Claude
    Mahon, Francois Xavier
    Guilhot, Francois
    CANCER, 2015, 121 (04) : 490 - 497
  • [38] Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia
    Bruemmendorf, Tim H.
    Gambacorti-Passerini, Carlo
    Bushmakin, Andrew G.
    Cappelleri, Joseph C.
    Viqueira, Andrea
    Reisman, Arlene
    Isfort, Susanne
    Mamolo, Carla
    ANNALS OF HEMATOLOGY, 2020, 99 (06) : 1241 - 1249
  • [39] Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study
    Shah, Neil P.
    Garcia-Gutierrez, Valentin
    Jimenez-Velasco, Antonio
    Larson, Sarah
    Saussele, Susanne
    Rea, Delphine
    Mahon, Francois-Xavier
    Levy, Moshe Yair
    Gomez-Casares, Maria Teresa
    Pane, Fabrizio
    Nicolini, Franck-Emmanuel
    Mauro, Michael J.
    Sy, Oumar
    Martin-Regueira, Patricia
    Lipton, Jeffrey H.
    LEUKEMIA & LYMPHOMA, 2020, 61 (03) : 650 - 659
  • [40] Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis
    Berdeja, Jesus G.
    Heinrich, Michael C.
    Dakhil, Shaker R.
    Goldberg, Stuart L.
    Wadleigh, Martha
    Kuriakose, Philip
    Cortes, Jorge
    Radich, Jerald
    Helton, Bret
    Rizzieri, David
    Paley, Carole
    Dautaj, Ilva
    Mauro, Michael J.
    LEUKEMIA & LYMPHOMA, 2019, 60 (10) : 2384 - 2393
12345